Drug development
Colin Kerr
Published: Monday, July 3, 2017
Novaliq GmbH has announced the successful application of a first-in-class ocular neuropathic pain and anti-inflammatory cannabinoid-based dry eye disease (DED) treatment approach, in collaboration with the University of Cologne, Germany.
“Based on solid results of our ongoing test series, we expect a significant impact of Novaliq’s first-in class Nov-07 programme, in comparison with existing DED drugs on an established DED mouse model,” said Philipp Steven MD, Principle Investigator, Ocular Surface Group at the Department of Ophthalmology, University of Cologne, Germany.
www.novaliq.com
Tags: industry
Latest Articles
Organising for Success
Professional and personal goals drive practice ownership and operational choices.
Update on Astigmatism Analysis
Is Frugal Innovation Possible in Ophthalmology?
Improving access through financially and environmentally sustainable innovation.
iNovation Innovators Den Boosts Eye Care Pioneers
New ideas and industry, colleague, and funding contacts among the benefits.
José Güell: Trends in Cornea Treatment
Endothelial damage, cellular treatments, human tissue, and infections are key concerns on the horizon.
Making IOLs a More Personal Choice
Surgeons may prefer some IOLs for their patients, but what about for themselves?
Need to Know: Higher-Order Aberrations and Polynomials
This first instalment in a tutorial series will discuss more on the measurement and clinical implications of HOAs.
Never Go In Blind
Novel ophthalmic block simulator promises higher rates of confidence and competence in trainees.
Simulators Benefit Surgeons and Patients
Helping young surgeons build confidence and expertise.